Stocktoria
Bluejay Diagnostics, Inc. BJDX
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2021-11-10
Bluejay Diagnostics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $249,040 | — |
| Gross profit | — | — | — | $48,911 | — |
| R&D expense | $3.0M | $3.5M | $5.7M | $4.2M | $1.1M |
| SG&A expense | — | — | $283,443 | $451,421 | — |
| Operating income | -$7.0M | -$7.2M | -$10.3M | -$9.3M | -$3.2M |
| Interest expense | — | — | — | — | $6,360 |
| Net income | -$6.8M | -$7.7M | -$10.0M | -$9.3M | -$3.5M |
| EPS (diluted) | $-15.25 | $-456.75 | $-3631.48 | $-9.22 | $-0.41 |
| Operating cash flow | -$6.1M | -$7.8M | -$8.3M | -$7.7M | -$4.4M |
| Free cash flow | -$6.2M | -$8.1M | -$9.0M | -$8.9M | -$4.4M |
| Cash & equivalents | $5.2M | $4.3M | $2.2M | $10.1M | $19.0M |
| Total assets | $7.1M | $6.7M | $4.9M | $13.5M | $21.0M |
| Total liabilities | $1.1M | $927,924 | $2.0M | $2.0M | $637,162 |
| Shareholders' equity | $6.0M | $5.7M | $2.9M | $11.5M | $20.4M |
Source: SEC EDGAR filings · CIK 0001704287 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.